Special issue on glucocorticoid therapy in rheumatic diseases: Introduction

NeuroImmunoModulation

Volumn 22, Issue , 2014, Pages 3-5

  Cutolo, Maurizio ^a   Chrousos, George P ^a   Pincus, Theodore ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTISONE ACETATE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; PREDNISOLONE; PREDNISONE; INTERLEUKIN 6; PLACEBO; ANTIRHEUMATIC AGENT; NEW DRUG;

CORTICOSTEROID THERAPY; EDITORIAL; HUMAN; MONOTHERAPY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); DENMARK; DISEASE COURSE; DISEASE DURATION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LONG TERM CARE; LOW DRUG DOSE; MORNING DOSAGE; MORNING STIFFNESS; MORTALITY; NETHERLANDS; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RUSSIAN FEDERATION; TREATMENT OUTCOME; VASCULITIS; HEMATOMA; REVIEW; SKIN DISEASE; RHEUMATIC DISEASES; DRUG MARKETING; FUNCTIONAL STATUS; OPTIMAL DRUG DOSE; PATIENT CARE;

ANTIRHEUMATIC AGENTS; GLUCOCORTICOIDS; HUMANS; RHEUMATIC DISEASES;

EID: 84908572090     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000362737     Document Type: Editorial

References (35)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF: The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of the pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949; 24: 181-197.
2. Hench PS: The reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adrenocorticotropic hormone. Ann Intern Med 1952; 36: 1-38.
3. Medical Resarch Council: Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 769-782.
4. Hill AB: Suspended judgment: memories of the British streptomycin trial in tuberculosis - The first randomized clinical trial. Controlled Clin Trials 1990; 11: 77-79.
5. Polley HF, Slocumb CH, Ward LE, Hench PS: Recognition and treatment of patients with chronic hypercortisonism. Ann Rheum Dis 1955; 14(4):416-417.
6. de Andrade JR, McCormick JN, Hill AGS: Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis 1964; 23: 158-162.
7. Empire Rheumatism Council: Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis: results of three years treatment. Ann Rheum Dis 1957; 16: 277-289.
8. West HF: Rheumatoid arthritis: The relevance of clinical knowledge to research activities. Abstr World Med 1967; 41: 401-417.
9. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti rheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492-509.
10. Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J, et al: Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009; 68: 1666-1672.
11. Zonana-Nacach A, Barr SG, Magder LS, Petri M: Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 2000; 43: 1801-1808.
12. Yelin E, Meenan R, Nevitt M, Epstein W: Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980; 93: 551-556.
13. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-872.
14. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA: Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 8-17.
15. Isomäki HA, Mutru O, Koota K: Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol 1975; 4: 205- 208.
16. Rasker JJ, Cosh JA: The natural history of rheumatoid arthritis: A fifteen year follow-up study: The prognostic significance of features noted in the first year. Clin Rheumatol 1984; 3: 11-20.
17. Pincus T, Callahan LF, Vaughn WK: Questionnaire, walking time and button test measures of functional capacity as predictive markers for mortality in rheumatoid arthritis. J Rheumatol 1987; 14: 240-251.
18. Harris ED Jr, Emkey RD, Nichols JE, Newberg A: Low dose prednisone therapy in rheumatoid arthritis: A double blind study. J Rheumatol 1983; 10: 713-721.
19. Kirwan JR: The effects of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-146.
20. Boers M, Verhoeven AC, Markusse HM, van de Laar MAFJ, Westhovens R, van Denderen JC, et al: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-318.
21. van Everdingen AA, Jacobs JWG, van Reesema DRS, Bijlsma JWJ: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. Ann Intern Med 2002; 136: 1-12.
22. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I: Low-dose prednisolone in addition to the initial diseasemodifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005; 52: 3360-3370.
23. Wassenberg S, Rau R, Steinfeld P, Zeidler H: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, doubleblind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371-3380.
24. Pincus T, Swearingen CJ, Luta G, Sokka T: Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: A randomised, double-blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009; 68: 1715- 1720.
25. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al: Low-dose prednisone inclusion in a methotrexatebased, tight control strategy for early rheumatoid arthritis: A randomized trial. Ann Intern Med 2012; 156: 329-339.
26. Montecucco C, Todoerti M, Sakellariou G, Scire CA, Caporali R: Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 2012; 14:R112.
27. Pincus T, Sokka T, Castrejón I, Cutolo M: Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res 2013; 65: 729-736.
28. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA- 1): A double-blind, randomised controlled trial. Lancet 2008; 371: 205-214.
29. Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, et al: Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013; 72: 204-210.
30. Danowski TS, Bonessi JV, Sabeh G, Sutton RD, Webster MW Jr, Sarver ME: Probabilities of pituitary-adrenal responsiveness after steroid therapy. Ann Intern Med 1964; 61: 11-26.
31. Wood JB, Frankland AW, James VH, Landon J: A rapid test of adrenocortical function. Lancet 1965; 1: 243-245.
32. Daly JR, Myles AB, Bacon PA, Beardwell CG, Savage O: Pituitary adrenal function during corticosteroid withdrawal in rheumatoid arthritis. Ann Rheum Dis 1967; 26: 18-25.
33. LaRochelle GE Jr, LaRochelle AG, Ratner RE, Borenstein DG: Recovery of the hypothalamic- pituitary-adrenal (HPA) axis in patients with rheumatic diseases receiving low-dose prednisone. Am J Med 1993; 95: 258-264.
34. Wei L, MacDonald TM, Walker BR: Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-770.
35. Pincus T, Sokka T, Stein CM: Are long-term very low doses of prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? Ann Intern Med 2002; 136: 76- 78.